|Bid||0.0000 x 1800|
|Ask||0.0000 x 900|
|Day's Range||1.7600 - 1.9300|
|52 Week Range||1.1200 - 5.2000|
|Beta (5Y Monthly)||3.01|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
James Oliviero has been the CEO of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) since 2015. This report will, first...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 20) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY )(announced ...
Investors can approximate the average market return by buying an index fund. Active investors aim to buy stocks that...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
Every investor in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) should be aware of the most powerful shareholder groups...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you want to compound wealth in the stock market, you can do so by buying an index fund. But i...
Checkpoint Therapeutics, Inc. (CKPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Checkpoint Therapeutics (CKPT) will be releasing highly anticipated interim data from its Phase I clinical trial this quarter. The readout will be for CK-301, an anti-PD-L1 antibody, which is expected to include safety and efficacy data from approximately 40-50 patients with a variety of tumor types including non-small cell lung cancer and cutaneous squamous cell carcinoma. The company is currently enrolling patients in three endometrial and colorectal cohorts that are anticipated to qualify for accelerated approval for one or more biologic license applications (BLAs).